MedTrace Logo

Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

NCT01655394 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2014-12-12

No results posted yet for this study

Summary

IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored.

Conditions

  • Guillain-Barre Syndrome
  • CIDP
  • Multifocal Motor Neuropathy

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Helmar C. Lehmann, PD Dr. med. · PI

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-12-31
Completion
2016-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01655394 on ClinicalTrials.gov